Table 1.
Meta-analysis of thirteen validated SNPs in the fatty acid synthesis pathway using two published melanoma GWAS datasets
| SNP | Allele1 | Gene | Position | MDACC (n=858) | NHS/HPFS (n=409) | Meta-analysis (n=1267) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EAF | HR (95% CI)2 | P2 | FPRP3 | EAF | HR (95% CI)4 | P4 | FPRP3 | Phet | I2 | HR (95% CI)5 | P5 | ||||
| rs37343986 | T>C | ELOVL2 | 6p24.2 | 0.41 | 0.72 (0.54–0.96) | 0.027 | 0.195 | 0.42 | 0.53 (0.33–0.83) | 0.005 | 0.076 | 0.265 | 19.44 | 0.66 (0.51–0.84) | 8.34×10−4 |
| rs37987137 | G>C | ELOVL2 | 6p24.2 | 0.43 | 0.68 (0.51–0.91) | 0.019 | 0.076 | 0.42 | 0.52 (0.33–0.82) | 0.005 | 0.067 | 0.326 | 0 | 0.63 (0.50–0.80) | 1.74×10−4 |
| rs110376836 | A>C | HSD17B12 | 11p11.2 | 0.06 | 2.10 (1.22–3.61) | 0.007 | 0.132 | 0.06 | 2.52 (1.42–4.46) | 0.002 | 0.060 | 0.650 | 0 | 2.29 (1.55–3.39) | 3.61×10−5 |
| rs110376846 | A>G | HSD17B12 | 11p11.2 | 0.06 | 2.10 (1.22–3.61) | 0.007 | 0.132 | 0.06 | 2.52 (1.42–4.46) | 0.002 | 0.060 | 0.650 | 0 | 2.29 (1.55–3.39) | 3.61×10−5 |
| rs618838087 | A>G | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.23 (1.21–4.10) | 0.010 | 0.198 | 0.983 | 0 | 2.24 (1.49–3.36) | 9.42×10−5 |
| rs618838097 | A>G | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.40 (1.33–4.33) | 0.004 | 0.108 | 0.875 | 0 | 2.32 (1.55–3.45) | 3.68×10−5 |
| rs618838117 | T>C | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.40 (1.33–4.33) | 0.004 | 0.108 | 0.875 | 0 | 2.32 (1.55–3.45) | 3.68×10−5 |
| rs618838447 | T>C | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.34 (1.30–4.23) | 0.005 | 0.125 | 0.924 | 0 | 2.29 (1.54–3.42) | 4.77×10−5 |
| rs618838457 | G>T | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.34 (1.30–4.23) | 0.005 | 0.125 | 0.924 | 0 | 2.29 (1.54–3.42) | 4.77×10−5 |
| rs175145537 | T>A | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.34 (1.30–4.23) | 0.005 | 0.125 | 0.924 | 0 | 2.29 (1.54–3.42) | 4.77×10−5 |
| rs175991147 | C>T | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.34 (1.30–4.23) | 0.005 | 0.125 | 0.924 | 0 | 2.29 (1.54–3.42) | 4.77×10−5 |
| rs175986877 | A>C | HSD17B12 | 11p11.2 | 0.06 | 2.25 (1.31–3.86) | 0.003 | 0.084 | 0.06 | 2.23 (1.21–4.10) | 0.010 | 0.198 | 0.983 | 0 | 2.24 (1.49–3.36) | 9.42×10−5 |
| rs777394527 | T>A | HSD17B12 | 11p11.2 | 0.06 | 2.22 (1.29–3.82) | 0.004 | 0.091 | 0.06 | 2.40 (1.33–4.33) | 0.004 | 0.108 | 0.849 | 0 | 2.30 (1.54–3.43) | 4.34×10−5 |
Abbreviations: SNP, single-nucleotide polymorphism; GWAS, genome-wide association study; MDACC, The University of Texas MD Anderson Cancer Center; NHS/HPFS, the Nurses’ Health Study and Health Professionals Follow-up Study; EAF, effect allele frequency; HR, hazards ratio; CI, confidence interval; FPRP, false positive report probability; Phet, P value for heterogeneity by Cochrane’s Q test; ELOVL2, elongation of very long-chain fatty acids 2; HSD17B12, hydroxysteroid dehydrogenase type 12;
Reference allele/effect allele;
Adjusted for age, sex, Breslow thickness, distant/regional metastasis, ulceration and mitotic rate in the additive model;
FPRP was used for multiple test correction because 85.1% of the analyzed SNPs in MDACC dataset were imputed with a high level of linkage disequilibrium;
Adjusted for age and sex in an additive genetic model;
Meta-analysis in the fix-effect model;
Genotyped SNPs in the MDACC dataset;
Imputed SNPs in the MDACC dataset.